Cagrilintide vs Semaglutide: Research Comparison
A Side-By-Side Research Comparison Of Cagrilintide And Semaglutide - an amylin analog versus a GLP-1 agonist in metabolic research. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| Cagrilintide | Semaglutide | |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Compound Class | Long-acting synthetic amylin analog (fatty acid-conjugated for once-weekly dosing) | GLP-1 receptor agonist; fatty-acid conjugated 31-amino-acid peptide analog of human GLP-1 |
| Evidence Tier | Investigational | Approved Drug |
| Molecular Target | Amylin receptor (AMY1-3, CTR + RAMP1/2/3 complexes) and calcitonin receptor (CTR); hypothalamic satiety signaling; gastric motility modulation | GLP-1 receptor (GLP1R); cAMP/PKA signaling; pancreatic beta-cell insulin secretion; hypothalamic appetite suppression; gastric emptying delay |
| Molecular Weight | 4409.01 Da | 4113.58 Da |
| Amino Acid Sequence | acylated cyclic amylin analog | 31-aa GLP-1 analog (Aib2, C18 diacid) |
| CAS Number | 1415456-99-3 | 910463-68-2 |
| Half-Life | ~1 week (weekly SC, acylated) | ~1 week |
| Studied For | Obesity / overweight, Type 2 diabetes, Combination with semaglutide (CagriSema), Amylin receptor agonism for satiety | Type 2 diabetes management, Chronic weight management / obesity, Cardiovascular risk reduction, HbA1c lowering |
About Cagrilintide
An investigational amylin weight-loss peptide, often paired with semaglutide.
Read The Full Cagrilintide MonographAbout Semaglutide
The approved GLP-1 weight-loss and diabetes drug; compounded versions carry FDA cautions.
Read The Full Semaglutide MonographKey Differences
- Evidence tier differs: Cagrilintide is classified as Investigational; Semaglutide is classified as Approved Drug.
- Reported half-life differs: Cagrilintide at ~1 week (weekly SC, acylated) versus Semaglutide at ~1 week.
- Primary molecular target differs: Cagrilintide acts on Amylin receptor (AMY1-3, CTR + RAMP1/2/3 complexes) and calcitonin receptor (CTR); hypothalamic satiety signaling; gastric motility modulation; Semaglutide acts on GLP-1 receptor (GLP1R); cAMP/PKA signaling; pancreatic beta-cell insulin secretion; hypothalamic appetite suppression; gastric emptying delay.
Continue Researching
Cagrilintide · Semaglutide · Compare Tool · Research Library
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.